logo

English
  • Svenska
  • About us
    About us
      • This is Calliditas
      • Vision and Strategy
      • Our Pipeline
      • Board of Directors
      • Management Team
      • Our History
      • Corporate Responsibility
      • Career
  • Science
    Science
      • IgA nephropathy
      • Nefecon
      • Orphan drugs
      • Other potential indications
  • Governance
    Governance
      • Corporate Governance
      • Corporate Governance Reports
      • Corporate Structure
      • General Meeting
        • Annual general meeting 2020
        • General meetings
      • Nomination Committee
        • Nomination committees
      • Board and Committees
        • Board of Directors
        • Board fees
        • Work of the Board of Directors
        • Committees
      • Management
        • Management team
      • Remuneration
      • Internal control and risk management
      • Auditor
      • Articles of Association
  • Investors
    Investors
      • The share
        • Trading information
        • Ownership structure
        • Share capital development
        • Dividend policy
        • Analyst coverage
      • Financial Reports and Presentations
      • SEC Filings
      • Archive old prospectuses
      • Press releases
      • Calendar
      • Subscribe
      • Contacts
      • Investor FAQs
      • Documentation Genkyotex tender offer
      • Capital Markets Day 2021
  • Media
    Media
      • Press releases
      • Calliditas in Media
      • Subscribe
      • Contacts
  • Contacts
    Contacts
      • Offices
      • Partnering
      • Investors
      • Media
  • Capital Markets Day 2021
  • Svenska

Press releases

Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Regulatory press releases
  • Non-regulatory press releases
  • All press releases
2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2012
  • 2010
  • 2009
  • 2008
  • All years
Mar 15, 2021

Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy

Feb 18, 2021

Year-End Report, 2020

Jan 28, 2021

Calliditas announces termination of the proposed global offering

Jan 26, 2021

Calliditas Therapeutics launches proposed global offering

Jan 20, 2021

Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day

  • Media
    • Press releases
    • Calliditas in Media
    • Subscribe
    • Contacts

Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

  • Privacy policy
  • About cookies

© Calliditas Therapeutics AB 2021